YR0104
Human IL-12 / IL-23 Monoclonal Antibody
Size
£355.00
- SKU:
- YR0104
- Additional Names:
- CLMF|CLMF2|IL-12B/P19|IL-23|IL-23A|IL23P19|IMD28|IMD29|NKSF|NKSF2|SGRF
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human IL-12 / IL-23
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P29460, Q9NPF7
- Synonyms:
- CLMF;CLMF p40;CLMF2;cytotoxic lymphocyte maturation factor 40 kDa subunit;IL-12 subunit p40;IL-12B;IL-23;IL-23 subunit alpha;IL-23-A;IL-23A;IL-23p19;IL12, subunit p40;IL23P19;IMD28;IMD29;interleukin 12, p40;interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40);interleukin 23 p19 subunit;interleukin 23, alpha subunit p19;interleukin-12 beta chain;interleukin-12 subunit beta;interleukin-23 subunit alpha;interleukin-23 subunit p19;interleukin-six, G-CSF related factor;JKA3 induced upon T-cell activation;natural killer cell stimulatory factor, 40 kD subunit;NK cell stimulatory factor chain 2;NKSF;NKSF2;P19;SGRF
- Extra Details:
- What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.
- Shipping Conditions:
- Blue Ice